Shikari Hasanain, Silva Paolo S, Sun Jennifer K
Beetham Eye Institute, Joslin Diabetes Center , Boston, Massachusetts , USA and.
Semin Ophthalmol. 2014 Sep-Nov;29(5-6):276-89. doi: 10.3109/08820538.2014.962167.
Intravitreal injections for the treatment of retinal disorders and intraocular infection have become a common ophthalmic procedure, and injections of anti-vascular endothelial growth factor agents or steroids are frequently performed for the treatment of diabetic macular edema or other diabetic vascular pathology. Diabetic patients may be at higher risk of adverse events than non-diabetic individuals given frequent systemic co-morbidities, such as cardiovascular and renal disease, susceptibility to infection, and unique ocular pathology that includes fibrovascular proliferation. Fortunately, many associated complications, including endophthalmitis, are related to the injection procedure and can therefore be circumvented by careful attention to injection techniques. This review highlights the safety profile of intravitreal injections in patients with diabetes. Although diabetic patients may theoretically be at higher risk than non-diabetic patients for complications, a comprehensive review of the literature does not demonstrate substantial increased risk of intravitreal injections in patients with diabetes.
玻璃体内注射用于治疗视网膜疾病和眼内感染已成为一种常见的眼科手术,并且抗血管内皮生长因子药物或类固醇的注射经常用于治疗糖尿病性黄斑水肿或其他糖尿病性血管病变。由于糖尿病患者经常伴有心血管和肾脏疾病等全身性合并症、易感染以及包括纤维血管增殖在内的独特眼部病理情况,他们可能比非糖尿病个体发生不良事件的风险更高。幸运的是,许多相关并发症,包括眼内炎,都与注射操作有关,因此通过仔细注意注射技术可以避免。本综述强调了糖尿病患者玻璃体内注射的安全性。虽然理论上糖尿病患者发生并发症的风险可能高于非糖尿病患者,但对文献的全面综述并未表明糖尿病患者进行玻璃体内注射的风险大幅增加。